drugset / Trial / NCT06598202
Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
Phase 1/2
Recruiting
38 enrolled
Xuanwu Hospital, Beijing
Shengqi Medical Technology (Guangzhou) Co., Ltd. · collabViyun (Xiamen) Biomedical Research Institute Co., Ltd. · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis.
Timeline
- Start
- 2024-12-01
- Primary completion
- 2026-05-30
- Completion
- 2026-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | exosomes derived from human umbilical cord blood mesenchymal stem cells | Other / unclassified | 1 ml | Intranasal |